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Cancer cells frequently exhibit dysregulation of the enzymes 
that control epigenetic modifications of the genome. For ex-
ample, three recent studies have suggested that DNA methyl-
transferases might play a key role in enabling cancer cells to 
evade recognition by the immune system by limiting the ex-
pression of endogenous retrotransposons (Chiappinelli et al., 
2015; Roulois et al., 2015; Goel et al., 2017). Pharmacological 
inhibition of DNA methylation could induce the expression 
of retrotransposons in cancer cells, which trigger an antiviral 
response that leads to tumor cell death. However, the exact 
mechanisms used by cancer cells to prevent the production 
of these retrotransposons are unknown. In this issue, Cuellar 
et al. report that SET DB1 is a gatekeeper of tumor survival 
that enables acute myeloid leukemia (AML) cells to evade in-
nate immune sensing of retrotransposons. An elevated level of 
SET DB1 in cancer cells promotes the formation of heteroch-
romatin at retrotransposons. This in turn prevents transcription 
of retrotransposon-derived double-stranded RNA (dsRNA), its 
downstream recognition by cytosolic RNA sensors, and the 
activation of a type I IFN response (Fig. 1).
Retrotransposons are a class of transposable elements that 
includes endogenous retroviruses (ERVs) and long interspersed 
nuclear elements (LINEs). Because of their viral origin, these 
elements can produce nucleic acids that can be distinguished 
as “nonself” rather than “self” by the immune system, which 
recognizes pathogen-specific molecules (pathogen-associated 
molecular patterns [PAMPs]). For example, LINEs have bi-
directional promoters and can produce dsRNA, and ERVs 
produce cytoplasmic DNA during reverse transcription. Both 
of these PAMPs activate IFN by binding to distinct pattern- 
recognition receptors (PRRs; Zeng et al., 2014). Retrotrans-
poson-derived nucleic acids have been proposed to modulate 
cancer survival and tumor immune responses. Indeed, several 
pioneering papers have recently revealed ERVs to be central to 
antitumor immunity through the sensing of dsRNA produced 
from them and the subsequent triggering of innate and adap-
tive immune responses (Chiappinelli et al., 2015; Roulois et al., 
2015; Goel et al., 2017). These papers show that immunostim-
ulatory ERVs are usually under epigenetic control that includes 
DNA methylation and that they can be reactivated with standard 
cancer drugs, such as those based on 5-azacytidine, which block 
DNA methylation, or by CDK4/6 inhibitors, which indirectly 
block DNA methylation (Chiappinelli et al., 2015; Roulois et 
al., 2015; Goel et al., 2017). However, although it is known that 
ERVs are controlled at the chromatin level in cancer cells, the 
epigenetic factors responsible for this immune masking of ret-
rotransposons remain obscure.
Cuellar et al. (2017) uncovered a role for SET DB1 in 
preventing retrotransposon recognition through an unbiased 
CRI SPR/Cas9 screen that focused on 350 epigenetic modifiers 
to identify factors essential for the survival and propagation of a 
human AML cell line. They show that SET DB1 is overexpressed 
in a broad range of cancers, including solid tumors, and that it 
is required for survival in five out of seven tested human AML 
cell lines. A recent study also shows that colorectal cancer cells 
are dependent on SET DB1 to survive a lethal dose of kinase in-
hibitors (Guler et al., 2017). Genetic ablation of SET DB1 leads 
to apoptosis, which is preceded by a striking up-regulation of 
IFN-stimulated genes (ISGs) in multiple cancer cell lines. Cuel-
lar et al. (2017) show that this induction of IFN production by 
depletion of SET DB1 correlates with increased expression of 
some ERVs, LINEs, and satellite repeats and a slight decrease 
in global H3K9 trimethylation (H3K9me3) levels (including at 
ERVs and LINEs), as well as at some zinc finger genes that 
are known targets of SET DB1. Of note, not all retrotrans-
posons are affected because there is no change in H3K9me3 
at HER VH integrants, for example. Interestingly, Cuellar et al. 
(2017) find that the loss of H3K9me3 after SET DB1 ablation 
occurs only in concert with neighboring unmodified, rather 
than acetylated, H3K14. This supports a function for SET DB1 
in inactive chromatin and indicates its potential collaboration 
with other cellular factors to target specific loci. Cuellar et al. 
(2017) verify that at key ISGs (of the IFN-induced protein with 
tetratricopeptide repeats or IFIT family), H3K9me3 is not af-
fected by SET DB1 knockout, suggesting that ISGs are acti-
vated after a bona fide immune response to the expression of 
retrotransposons. Most remarkably, Cuellar et al. (2017) show 
that SET DB1 knockout cells produce dsRNA, which is readily 
detected by antibody staining, and that ERVs and LINEs exhibit 
the bidirectional transcription required for dsRNA formation. 
Finally, the authors demonstrate that SET DB1-mediated ISG 
Cancer cells thrive on genetic and epigenetic changes that 
confer a selective advantage but also need strategies to 
avoid immune recognition. In this issue, Cuellar et al. 
(2017. J.  Cell Biol. https ://doi .org /10 .1083 /jcb 
.201612160) find that the histone methyltransferase 
SET DB1 enables acute myeloid leukemia cells to evade 
sensing of retrotransposons by innate immune receptors.
Cancer cells, on your histone marks, get SET DB1, 
silence retrotransposons, and go!
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induction and cell death depend on RNA sensing by the cytoso-
lic PRRs MDA5 and RIG-I.
Although Cuellar et al. (2017) provide evidence that 
SET DB1-regulated retrotransposons are involved in this mech-
anism of innate sensing, it is unclear which ones are most rele-
vant in producing immunostimulatory nucleic acids. With ERVs 
and LINEs together comprising at least 25% of the human ge-
nome, this is a difficult yet important question to pursue in fu-
ture work. Another interesting possibility raised by this work 
is that SET DB1 may control natural immune responses at the 
chromatin level through the regulated reactivation of retrotrans-
posons in certain contexts, as ERVs can enhance T-independent 
B cell responses (Zeng et al., 2014) and SET DB1 prevents ERV 
expression by B cells (Collins et al., 2015). Further work will 
also be necessary to determine whether SET DB1, like TREX1, 
is required to prevent downstream sensing of DNA produced 
from retrotransposons that are competent for reverse transcrip-
tion through the cGAS–STI NG pathway (Zeng et al., 2014; 
Thomas et al., 2017), as well as its role defined here in prevent-
ing RNA sensing (Cuellar et al., 2017).
The regulation of immunity by retrotransposons is an 
emerging field in which the identification by Cuellar et al. (2017) 
of SET DB1 as a key regulator of ERVs in cancer cells paves the 
way for further research on this topic. Importantly, it builds on 
previous landmark work that has defined SET DB1 as a director of 
the epigenetic silencing of ERVs in embryonic stem cells, murine 
embryonic fibroblasts, and B cells (Matsui et al., 2010; Collins et 
al., 2015; Tie and Rowe, 2017). However, this ability of SET DB1 
to repress ERVs in these noncancerous cell types raises the im-
portant question of whether SET DB1 can be selectively targeted 
by novel drugs without off-target effects on the genome and epig-
enome. New SET DB1-targeting cancer drugs are an important 
area of development that could prove valuable in a range of can-
cers, all bearing the hallmark of SET DB1 dependence. Future 
work into the mechanism of SET DB1 repression of retrotrans-
posons in cancer cells will reveal whether it involves the same 
components that are required for ERV silencing early in develop-
ment (Tie and Rowe, 2017), or perhaps components of the RNA 
interference machinery as proposed by Cuellar et al. (2017), or 
both. An understanding of all the epigenetic and related factors 
necessary for this mechanism should lead to the identification of 
additional, perhaps more specific, druggable therapeutic targets.
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